Novartis Sp ADR (NVS)
$109.25
0.20 (0.18%)
NVS Stock Quote Delayed 30 Minutes
Biogen Is in the Right Place at the Right Time
BIIB's promising multiple scerlosis drug BG-12 could be a huge winner, just when Novartis' entry is stumbling.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$108.92
Market Cap
215.13B
PE Ratio
18.61
EPS
5.87
Volume (Avg. Vol.)
2.31M
Day's Range
$108.02 - $109.07
52-Week Range
$92.35 - $120.92
Dividend & Yield
$3.74 (3.42%)
NVS Stock Predictions, Articles, and Novartis Sp ADR News
Study Results Boost Analyst’s Forecast for Novartis Drug
An analyst boosts his forecast for Novartis' Afinitor based on its promise as a treatment for breast cancer.
In Event of Bird Flu Pandemic, Vaccine Producers Likeliest to Prosper
A mutant strain of H5N1 could be spreading in Asia, meaning vaccine heavyweights might be going back to the drawing board.
Insider Bets Big That Seattle Genetics Cancer Drug Can Buck Dendreon Effect
Similar drugs in Adcetris' high price range also faring well, which is cause for optimism, but SGEN's lack of other drugs near the end of the pipeline should make investors wary.
More Tightly Focused Biogen Appears to Have Greater Upside
With many of its drugs in Phase III clinical trials, including a promising treatment for MS, Biogen has upside potential.
Aftermath of August’s Intraday Low
A week after the stock market formed its intraday low, the rebound is still shaky. For now, investors should be selective with new purchases.
Big Pharma Banking on New Cancer Treatment Approach to Boost Sales
GlaxoSmithKline, Eli Lilly and Novartis are among the companies studying epigenetics -- a new approach to fighting cancer that is already seeing some success.
Deep-Pocket Drug Companies Poised to Reap Biosimilar Rewards
Only a few companies have the massive resources needed to get going in the upcoming "biosimilars" boom. Who will lead the charge?
Novartis Shifts Strategy to Reinforce Growth
Can Novartis' focus on generics and emerging markets counteract the loss of key patent protections?
